Ask AI
ProCE Banner Activity

Experts Discuss Contemporary HER2-Directed Treatment in Advanced Gastroesophageal Biliary Tract Cancers

Clinical Thought

HER2-directed treatment strategies in gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC) continue to evolve, with the FDA recently approving first-line zanidatamab-based treatment strategies for advanced GEA based on data from the phase III HERIZON-GEA-01 trial. In this commentary, expert faculty discuss key questions surrounding HER2-targeted therapy in these GI cancers.

Released: July 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals involved in the care of patients with gastroesophageal adenocarcinoma and biliary tract cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply guideline-concordant HER2 testing and interpretation strategies for GEA and BTC, including appropriate integration of pathology results with PD-L1 status and broader molecular profiling

  • Critically evaluate newly presented and recently reported clinical trial data in HER2-positive GEA and BTC, distinguishing established standards from investigational approaches

  • Individualize treatment selection and sequencing for patients with HER2-positive GEA and BTC based on disease setting, prior therapy, biomarker profile, comorbidities, toxicity risk, and patient goals

  • Implement proactive monitoring and mitigation strategies for clinically relevant toxicities associated with HER2-directed therapies

  • Identify appropriate patients for referral to clinical trials evaluating novel HER2-directed agents and combinations in GI malignancies

Financial Disclosures

Primary Author

Michel Ducreux, MD, PhD: consultant/advisor/speaker: Astellas, Bayer, BMS, Daiichi Sankyo, Incyte, Jazz Pharma, Merck Serono, Revolution Medicines, Takeda.

Geoffrey Ku, MD: consultant/advisor/speaker: Astellas, AstraZeneca, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Gilead, I-Mab/NovaBridge, Jazz, Merck, Oncolys; researcher: Astellas, CARsgen, BeOne, I-Mab/NovaBridge, Jazz, Merck, Oncolys; other financial or material support: Dava Oncology.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.